spec sheet9 rows
Bevacizumab A monoclonal antibody that binds vascular endothelial growth factor A and stops new blood vessels forming. It has been an intravenous cancer drug since 2004 and was used off-label in the eye for two decades; in July 2026 the FDA approved Lytenava, the first ophthalmic formulation, for wet age-related macular degeneration.
- Restores vision rather than only preserving it in wet age-related macular degeneration
- Equivalent to ranibizumab on vision in two independent randomised trials
- A fraction of the cost of the licensed alternatives
- Now available in a formulation actually made for the eye rather than repackaged from an infusion vial
- Two decades of accumulated real-world use behind it
- Conjunctival haemorrhage in 8.8 percent of the ophthalmic trial
- Raised intraocular pressure after injection
- Endophthalmitis, retinal detachment and intraocular inflammation as the defining risks of the injection itself
- Systemically, hypertension, bleeding, impaired wound healing and gastrointestinal perforation, which belong to the intravenous cancer dose
Overview
Bevacizumab is a humanised monoclonal antibody against vascular endothelial growth factor A, the signal that tells endothelial cells to build new blood vessels. Tumours use that signal to grow their own blood supply, which is what made it an anticancer drug [5]; the wet form of age-related macular degeneration uses the same signal to grow leaky vessels under the retina, which is what made ophthalmologists reach for it.
The second use arrived by an unusual route. Bevacizumab was never developed for the eye, but a vial intended for an intravenous cancer dose could be split into many tiny doses, and retinal specialists began injecting it into eyes off-label because it worked and cost a fraction of the approved alternatives. Publicly funded head-to-head trials then tested whether the cheap improvised option was as good as the licensed one. In CATT, 1,208 patients randomised to bevacizumab or ranibizumab on matched schedules gained 8.0 and 8.5 letters of vision respectively at one year, an equivalent result [2]. GEFAL, 501 patients in 38 French centres, found the same with a noninferiority margin of five letters [3]. Reviews put the cost difference at over twenty thousand dollars per patient per year [4].
What none of that produced was a formulation made for the eye. Every off-label dose came from a vial designed for a vein, repackaged by a compounding pharmacy, with the sterility and consistency risks that implies. ONS-5010, an ophthalmic formulation, was tested in NORSE TWO against ranibizumab: 41.7 percent of patients gained at least 15 letters against 23.1 percent, with a mean gain of 11.2 letters against 5.8 at eleven months [1]. The FDA approved it as Lytenava on 24 July 2026 after three complete response letters, making it the first bevacizumab licensed for the eye in the United States. It had already been authorised in the European Union and the United Kingdom, where it is named bevacizumab gamma.
- For roughly twenty years, most bevacizumab injected into eyes came from vials designed for intravenous cancer infusion, split by compounding pharmacies into doses a fraction of the size.
- CATT randomised 1,208 patients and found bevacizumab and ranibizumab equivalent on vision, 8.0 letters gained against 8.5 on matched monthly dosing [2].
- The cost gap was the reason the trials were run at all; one review put the difference at over twenty thousand dollars per patient per year [4].
- In the ophthalmic formulation's own trial, 41.7 percent of patients gained three lines of vision or more, against 23.1 percent on the comparator [1].
- The FDA issued three complete response letters before approving the eye formulation.
- It is called bevacizumab gamma in Europe and the United Kingdom and bevacizumab-vikg in the United States, and it is the same molecule as Avastin.
Mechanism
Vascular endothelial growth factor A is a soluble protein that binds VEGF receptors on endothelial cells and instructs them to proliferate, migrate and form new vessels, and to make existing vessels leaky. Bevacizumab is an antibody that binds VEGF-A itself rather than the receptor, so the signal is intercepted before it arrives.
In a tumour, that starves the growing mass of the blood supply it needs to expand beyond a few millimetres and normalises the chaotic vessels it has already built, which is why it was developed alongside chemotherapy rather than instead of it [5].
In the eye, the same interception is doing something more specific. In wet age-related macular degeneration, new vessels grow from the choroid through Bruch's membrane and leak fluid and blood under the macula; the fluid is what distorts and destroys central vision. Neutralising VEGF-A dries the retina and lets vision recover, which is why the treatment effect shows up as letters gained on a chart rather than merely as vision preserved [1] [2].
The route decides the risk. Systemically, blocking angiogenesis everywhere carries hypertension, impaired wound healing, bleeding and thrombosis. Injected into the vitreous, the dose is a fraction of the intravenous one and stays largely in the eye, but the injection itself is a hole through the wall of the eye.
receptor fingerprint
VEGF-AInhibitor
Choroidal neovascularisationInhibitor
Tumour angiogenesisInhibitor
Safetyrisks and cautions, not medical advice
The two routes have almost nothing in common on safety.
In the eye, the ophthalmic trial reported one study-related serious ocular adverse event, raised intraocular pressure, and gave conjunctival haemorrhage as the most common adverse event at 8.8 percent [1]. The risks that define intravitreal injection as a procedure are endophthalmitis, retinal detachment, intraocular inflammation and a pressure spike, each uncommon per injection and repeated monthly for as long as treatment continues.
Systemically, CATT found death, myocardial infarction and stroke at similar rates for bevacizumab and ranibizumab, but the proportion of patients with serious systemic adverse events was higher with bevacizumab, 24.1 percent against 19.0 percent, with the excess spread across disease categories that were not the ones anyone had predicted; the trial said explicitly that the difference required further study rather than explaining it [2]. GEFAL, smaller, found 12.6 percent against 12.1 percent and no significant difference [3]. That disagreement has never been fully resolved, and it is the honest reason the drug's ocular safety is discussed as a live question rather than a settled one.
The intravenous oncology dose carries a different and much heavier list, including hypertension, proteinuria, impaired wound healing, haemorrhage, arterial thromboembolism and gastrointestinal perforation. None of that transfers to the eye dose, and none of the eye data reassures about the vein.
History
Bevacizumab was developed at Genentech as an antibody against VEGF-A and entered late-stage colorectal cancer trials in the early 2000s, when angiogenesis inhibition was still an unproven idea and two candidates, bevacizumab and the small molecule SU5416, were racing each other [5]. It was approved as Avastin in 2004 and went on to indications across colorectal, lung, renal, cervical and ovarian cancer and glioblastoma.
The eye story ran in parallel and unofficially. From around 2005 retinal specialists injected repackaged Avastin into eyes off-label, because it worked and because the licensed alternatives cost roughly forty times as much. Publicly funded trials, CATT in the United States and GEFAL in France, were run specifically to test whether the improvised option was equivalent, and found that it was [2] [3]. What stayed missing was a product actually made for the eye. Outlook Therapeutics ran the NORSE programme with ONS-5010 [1], received marketing authorisation in the European Union and the United Kingdom as Lytenava, bevacizumab gamma, and, after three complete response letters from the FDA, was approved in the United States on 24 July 2026 as bevacizumab-vikg.
Reputation
In oncology, bevacizumab is a long-established and somewhat deflated drug: real but usually modest gains, a heavy toxicity list, and indications that have narrowed as better options appeared. In ophthalmology its reputation is entirely different, and it is one of the clearest cases in modern medicine of a cheap improvised practice being validated rather than suppressed. Two decades of off-label use, backed by publicly funded head-to-head trials, saved health systems enormous sums without costing patients vision [2] [3]. The approval of an ophthalmic formulation is best read as a correction of a long-standing anomaly rather than as a new therapy: the drug was already the standard of care in much of the world, and what was missing was a vial made for the job.
Subjective profileweighing the evidence above
In the eye, one of the best value interventions in medicine, and the approval of an ophthalmic formulation finally supplies properly what retinal specialists have been improvising from cancer vials for twenty years. It restores vision rather than merely holding the line, and two independent randomised trials put it level with drugs costing many times more. Two things stay unsettled: CATT's excess of serious systemic adverse events was never explained, and the injections do not stop. In oncology it is a different and much heavier drug with a much less impressive record, and nothing about the eye data should be read across to it.
Resources
No suppliers are provided for compounds like this. This entry is here for reference.
Research
- 1.ONS-5010 (bevacizumab-vikg) Safety and Efficacy in Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration.
- 2.Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
- 3.Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
- 4.Bevacizumab for the treatment of neovascular age-related macular degeneration.
- 5.Targeting vascular endothelial growth factor in colorectal cancer.
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is Lytenava the same drug as Avastin?
Same molecule, different product. Avastin is the intravenous formulation for cancer. Lytenava is an ophthalmic formulation of bevacizumab made for injection into the eye, named bevacizumab-vikg in the United States and bevacizumab gamma in Europe and the United Kingdom.
Why did it take until 2026 to approve bevacizumab for the eye?
Nobody had a commercial reason to develop it. The drug was already being used off-label from repackaged cancer vials at a fraction of the price of the licensed alternatives, so the incentive to fund an ophthalmic programme was weak. Outlook Therapeutics eventually ran one, and it took three complete response letters to get through.
Does it work as well as the licensed alternatives?
On vision, yes. CATT randomised 1,208 patients and found 8.0 letters gained with bevacizumab against 8.5 with ranibizumab on matched monthly dosing. GEFAL, an independent French trial of 501 patients, reached the same conclusion.
Is injecting into the eye as bad as it sounds?
It is a real procedure with real risks: infection inside the eye, retinal detachment, inflammation and a pressure spike, each uncommon per injection. It is also done routinely and in enormous numbers. The alternative in untreated wet macular degeneration is losing central vision.
Were there safety concerns with the off-label use?
One that was never resolved. CATT found serious systemic adverse events in 24.1 percent of bevacizumab patients against 19.0 percent on ranibizumab, spread across categories nobody had predicted, and said the difference needed further study. The smaller GEFAL trial found no difference. That disagreement stands.
Limitations of the evidence
- CATT found more serious systemic adverse events with bevacizumab than ranibizumab, 24.1 against 19.0 percent, and did not explain it
- Injections continue indefinitely; there is no course that ends
- The eye data say nothing about the safety of the intravenous oncology dose, and the reverse is also true
- The ophthalmic approval took three complete response letters
- In oncology the survival gains have generally been modest against a substantial toxicity list
Adverse effects
- Conjunctival haemorrhage in 8.8 percent of the ophthalmic trial
- Raised intraocular pressure after injection
- Endophthalmitis, retinal detachment and intraocular inflammation as the defining risks of the injection itself
- Systemically, hypertension, bleeding, impaired wound healing and gastrointestinal perforation, which belong to the intravenous cancer dose
Notes and cautions
- The eye dose and the cancer dose are the same molecule used at completely different scales, by different routes, with different risks; the two should never be reasoned about together.
- Off-label intravitreal bevacizumab remains widely used worldwide and the approval of an ophthalmic formulation does not make that practice unsafe, only better supplied.